ARS Pharmaceuticals (SPRY) Expected to Release Quarterly Earnings on Thursday

Key Points

• ARS Pharmaceuticals is expected to report Q3 2026 results on November 5, with analysts forecasting a loss of $0.34 per share and revenue of $41.99 million.
• The company’s prior quarter missed EPS expectations, reporting a $0.63-per-share loss versus the expected $0.48 loss, although revenue exceeded estimates at $33.66 million.
• SPRY shares recently traded near $3.66, close to their 52-week low, while analysts maintain a “Moderate Buy” consensus and an average price target of $25.00.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) is expected to be releasing its Q3 2026 resultson Thursday, November 5th. Analysts expect the company to announce earnings of ($0.34) per share and revenue of $41.99 million for the quarter. Investors are encouraged to explore the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 AM ET.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.15). ARS Pharmaceuticals had a negative net margin of 184.24% and a negative return on equity of 256.67%. The firm had revenue of $33.66 million during the quarter, compared to the consensus estimate of $31.32 million. On average, analysts expect ARS Pharmaceuticals to post ($1.91) EPS for the current fiscal year and ($0.88) EPS for the next fiscal year.

ARS Pharmaceuticals Trading Up 0.3%

Shares of NASDAQ:SPRY opened at $3.66 on Friday. ARS Pharmaceuticals has a 52-week low of $3.53 and a 52-week high of $13.15. The company has a debt-to-equity ratio of 13.72, a quick ratio of 3.28 and a current ratio of 3.48. The company has a market capitalization of $363.99 million, a P/E ratio of -1.68 and a beta of 0.85. The company has a 50-day simple moving average of $4.62 and a 200 day simple moving average of $7.46.

Analysts Set New Price Targets

SPRY has been the topic of several research analyst reports. Leerink Partners set a $15.00 price objective on ARS Pharmaceuticals in a research note on Tuesday, September 8th. Weiss Ratings downgraded ARS Pharmaceuticals from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Monday, August 17th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, ARS Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $25.00.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc NASDAQ: SPRY is a biopharmaceutical company focused on developing and commercializing treatments for severe allergic reactions. The company's lead product is neffy (epinephrine nasal spray), a needle-free alternative to injectable epinephrine designed for the emergency treatment of allergic reactions, including anaphylaxis.

Neffy was approved by the U.S. Food and Drug Administration in 2024 for adults and pediatric patients who weigh at least 30 kilograms. The product is intended to provide rapid, convenient administration without requiring a syringe or injector, which may help address barriers associated with the use of traditional epinephrine auto-injectors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.